Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE0005664809
Wed, 14.08.2024
Evotec SE
Softness in market for Shared R&D Services, with H1 2024 revenues down 7% year-on-year. Continued growth of sales order book in Discovery – higher share of integrated long-term deals will improve revenue contribution beyond 2024
Strong progress of Just – Evotec Biologics with H1 2024 revenues increase of 50% year-on-year; capacity r [ … ]
Tue, 13.08.2024
Evotec SE
Key scientific achievements drive the expansion of the pipeline of molecular glue degraders
Performance-based and programme-based payments of in total US$ 75 m to Evotec
Hamburg, Germany, 13 August 2024:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced further strong progr [ … ]
Thu, 08.08.2024
Evotec SE
Key scientific achievement advances the joint neuroscience pipeline and earns a payment of US$ 25 m to Evotec to progress further research
Hamburg, Germany, 08 August 2024:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced progress within the Company’s strategic partnership wit [ … ]
Wed, 07.08.2024
Evotec SE
Hamburg, Germany, 07 August 2024:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for the first half-year of 2024 on Wednesday, 14 August 2024.
The Company is going to hold a conference call to discuss the results as well as provide an update on its performance. The con [ … ]
Tue, 06.08.2024
Evotec SE
Navigating through a challenging H1 2024: Unsatisfying revenue dynamics in Shared R&D; Just – Evotec Biologics with mid double-digit revenue growth versus strong comparable basis
Adjusted EBITDA impacted by high fixed cost base in Shared R&D and ramp-up costs for J.POD Toulouse, France
Further strengthened sales order book i [ … ]
Tue, 06.08.2024
Evotec SE
Ad hoc: Evotec SE provides guidance update
Hamburg, Germany, – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces that it has refined its guidance for the fiscal year 2024.
The Company expects Group revenues in the range of € 790 – 820 m (low to mid-single-digit percent [ … ]
Wed, 10.07.2024
Evotec SE
Multi-year collaboration will initially focus on early discovery research for metabolic and infectious diseases
Hamburg, Germany, 10 July 2024:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced it has entered into a multi-year master research collaboration and option and licens [ … ]
Mon, 08.07.2024
Evotec SE
Just – Evotec Biologics expands partnership with Sandoz for development and commercial manufacturing of biosimilars
Additional biosimilars potentially to be added to Sandoz development pipeline
Further guarantees for Sandoz long-term commercial supply security
Hamburg, Germany, and Seattle, WA, USA, 8 July 2024:
Evotec SE [ … ]
Tue, 25.06.2024
Evotec SE
Just – Evotec Biologics will deliver an ultra-rapid, cost-efficient biotherapeutics manufacturing platform solution for the DOD’s Manufacturing Optimization Program
Manufacturing solution includes seamless integration of accelerated mAb drug development into the overall Manufacturing Optimization Program
Manufacturing Optimization P [ … ]
Wed, 12.06.2024
Evotec SE
Key scientific achievement advances the joint pipeline in the strategic neuroscience partnership with Bristol Myers Squibb and earns a payment of US$ 20 m to Evotec to progress further research
Hamburg, Germany, 12 June 2024:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today th [ … ]